ENTA logo

ENTA
Enanta Pharmaceuticals Inc

1,160
Mkt Cap
$363.03M
Volume
199,672.00
52W High
$17.15
52W Low
$4.09
PE Ratio
-3.90
ENTA Fundamentals
Price
$12.51
Prev Close
$13.00
Open
$13.00
50D MA
$13.51
Beta
1.11
Avg. Volume
200,257.19
EPS (Annual)
-$3.84
P/B
2.87
Rev/Employee
$544,366.67
$267.58
Loading...
Loading...
News
all
press releases
Enanta Pharmaceuticals Pitches RSV Phase 3 Plans, Expands Oral Immunology Pipeline at Citizens Conference
Enanta Pharmaceuticals (NASDAQ:ENTA) used a presentation at the Citizens Life Sciences Conference to outline its evolving pipeline strategy, highlighting late-stage ambitions in respiratory syncytial...
MarketBeat·7d ago
News Placeholder
More News
News Placeholder
Commodore Capital LP Buys New Holdings in Enanta Pharmaceuticals, Inc. $ENTA
Commodore Capital LP purchased a new position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund...
MarketBeat·8d ago
News Placeholder
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that...
Business Wire·20d ago
News Placeholder
What Makes Enanta Pharmaceuticals (ENTA) a New Buy Stock
Enanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·1mo ago
News Placeholder
Equities Analysts Issue Forecasts for ENTA Q2 Earnings
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - Research analysts at HC Wainwright raised their Q2 2026 EPS estimates for Enanta Pharmaceuticals in a report released on Tuesday, February...
MarketBeat·1mo ago
News Placeholder
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of +21.50% and +19.52%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Enanta Pharmaceuticals (NASDAQ:ENTA) Posts Earnings Results, Beats Estimates By $0.12 EPS
Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) posted its earnings results on Monday. The biotechnology company reported ($0.42) earnings per share for the quarter, beating the consensus...
MarketBeat·1mo ago
News Placeholder
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial...
Business Wire·1mo ago
News Placeholder
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by Brokerages
Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven research firms that are covering the firm, MarketBeat...
MarketBeat·2mo ago
News Placeholder
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections and immunological...
Business Wire·3mo ago
<
1
2
...
>

Latest ENTA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.